Enterprise Value
750M
Cash
551.4M
Avg Qtr Burn
-23.6M
Short % of Float
10.34%
Insider Ownership
0.79%
Institutional Own.
-
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Obexelimab (CD19) Details Lupus nephritis | Phase 3 Update | |
Vudalimab (XmAb®717) (PD-1 x CTLA-4) Details Renal cell carcinoma, Cancer, Prostate cancer | Phase 2 Data readout | |
Vudalimab (XmAb®717) (PD-1 x CTLA-4) Details Cancer, Non-small cell lung carcinoma | Phase 2 Initiation | |
XmAb662 (IL12-Fc) Details Cancer, Solid tumor/s | Phase 1 Data readout | |
Plamotamab (CD20xCD3) Details Non-Hodgkin lymphoma, B-cell malignancies, Chronic lymphocytic leukemia | Phase 1 Update | |
XmAb564 (IL-2-Fc) Details Autoimmune disease, Psoriasis, Atopic dermatitis | Phase 1a Update | |
Vibecotamab (CD123xCD3) Details Acute myeloid leukemia | Failed Discontinued | |
Tidutamab (SSTR2xCD3) Details Cancer, Neuroendocrine tumor, Gastrointestinal stromal tumors | Failed Discontinued |